Lexatumumab
Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TRAIL-R2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6346H9832N1720O2002S42 |
Molar mass | 143.6 kg/mol g·mol−1 |
|
HGS-ETR2 antibodies were generated by HGS through a collaboration with Cambridge Antibody Technology.[2]
Development was discontinued in 2015.[3]
References
- Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab, American Medical Association.
- "Archived copy". Archived from the original on 2008-05-16. Retrieved 2010-05-12.CS1 maint: archived copy as title (link)
- "Lexatumumab - AdisInsight". adisinsight.springer.com.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.